Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Genomics Tool Company's Transition From Research to the Clinic

This article was originally published in Start Up

Executive Summary

The late 1990s genomics implosion spurred many genomics tools companies focusing on research laboratories to re-direct their attention to the clinic. The expectation was that innovative diagnostic tests and analytic platforms could do for them what collapsing research markets couldn't. Among those hit hard was Third Wave Technologies Inc., which was forced to re-evaluate its priorities and step up the pace of its commercialization timetable, while reducing emphasis on research. TWT's struggles are similar to those of other genomics companies facing the same tough environment, but its story is also universally applicable to medical device startups, which start with a strong scientific orientation and, often painfully, need to make business their major priority.

You may also be interested in...



Qiagen Buys Molecular Staging: Stalking PCR

Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen's recent acquisition of the assets of Molecular Staging, one of the sector's pioneers, reflects the promise and limitations of a field in which competition is fierce, development time is lengthy, and technology is evolving much faster than general market acceptance.

Qiagen Buys Molecular Staging: Stalking PCR

Although scientific and clinical interest in molecular diagnostics is at an all-time high, companies are still struggling to find the right business model for the field. Qiagen's recent acquisition of the assets of Molecular Staging, one of the sector's pioneers, reflects the promise and limitations of a field in which competition is fierce, development time is lengthy, and technology is evolving much faster than general market acceptance.

ThirdWave Pushes for Parity

Third Wave Technologies wants its Invader technology to be as ubiquitous as PCR. Since a deal with potential buyer Applera fell through two years ago, the company has begun several high-profile collaborations, including one with the Japanese SNP initiative, which now accounts for 50% of revenues. Its efforts appear to be paying off, but the company is fighting an uphill battle in an intensely competitive field.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel